A high-throughput phenotypic screen combined with an ultra-large-scale deep learning-based virtual screening reveals novel scaffolds of antibacterial compounds
Gabriele Scalia, Steven T. Rutherford, Ziqing Lu, Kerry R. Buchholz, Nicholas J. Skelton, Kangway V. Chuang, Nathaniel Diamant, Jan-Christian Hütter, Jerome-Maxim Luescher, Anh Miu, Jeff Blaney, Leo Gendelev, Elizabeth Skippington, Gregory J. Zynda, Nia Dickson, Michał Koziarski, Yoshua Bengio, Aviv Regev, Man‐Wah Tan, Tommaso Biancalani · bioRxiv (Cold Spring Harbor Laboratory) · 2024
ABSTRACT The proliferation of multi-drug-resistant bacteria underscores an urgent need for novel antibiotics. Traditional discovery methods face challenges due to limited chemical diversity, high costs, and difficulties in identifying structurally novel compounds. Here, we explore the integration of small molecule high-throughput screening with a deep learning-based virtual screening approach to uncover new antibacterial compounds. Leveraging a diverse library of nearly 2 million small molecules, we conducted comprehensive phenotypic screening against a sensitized Escherichia coli strain that, at a low hit rate, yielded thousands of hits. We trained a deep learning model, GNEprop, to predict antibacterial activity, ensuring robustness through out-of-distribution generalization techniques. Virtual screening of over 1.4 billion compounds identified potential candidates, of which 82 exhibited antibacterial activity, illustrating a 90X improved hit rate over the high-throughput screening experiment GNEprop was trained on. Importantly, a significant portion of these newly identified compounds exhibited high dissimilarity to known antibiotics, indicating promising avenues for further exploration in antibiotic discovery.